SpliSense Secures Up to $13 Million from the Cystic Fibrosis Foundation to Advance Phase 2b Study of SPL84 for Cystic Fibrosis

Cystic Fibrosis Foundation funding follows positive SPL84 Phase 2a clinical results demonstrating the first-ever clinical proof-of-concept for an inhaled antisense oligonucleotide therapy in a lung diseaseFunding supports the ongoing global Phase 2b study evaluating SPL84 in people with…

Read the full release →

News provided by PR Newswire.